Compare Diamondback Energy Inc (FANG) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Medpace Holdings Inc — how do they compare? Diamondback Energy Inc trades at $201.5 (market cap $56.48B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Diamondback Energy Inc is far larger — about 3.3× Medpace Holdings Inc's market cap, and Diamondback Energy Inc pays a 2.18% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| FANG | MEDP | |
|---|---|---|
Market Cap | $56.48B | $16.90B |
Sector | Energy | Technology |
52-Week High | $213.69 | $620.59 |
52-Week Low | $134.53 | $393.42 |
Enterprise Value | $68.63B | $16.52B |
Dividend Yield | 2.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $200.97, up 1.01% today, with bullish technical signals and strong earnings beats in Q1 and Q2 2026. The stock benefits from high oil prices, production growth, and a 90% analyst buy rating. Recent news highlights Q2 earnings surpassing estimates, driven by operational efficiency and raised 2026 output guidance. Cash flow from operations improved to $8.76 billion in 2025, though net income margin declined to 8.64%.
The outlook is positive, with a consensus price target of $236.63 offering ~18% upside, supported by debt reduction and Permian Basin strength. Risks include oil price volatility, margin pressure from rising costs, and geopolitical supply disruptions affecting global markets. Institutional inflows, like Balefire LLC's recent purchase, reinforce confidence in growth prospects.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
